Illinois Appellate Court Expands Learned Intermediary Doctrine to NICU Formula Cases

In Watson v. Mead Johnson & Company, LLC, the Illinois Appellate Court, Fifth District, issued one of the year's most significant product liability decisions, reversing a $60 million plaintiff's verdict and ordering a new trial. While the case arose from tragic facts involving a premature infant who developed necrotizing enterocolitis (NEC), the court's opinion reaches far beyond infant formula litigation. The decision provides important guidance on the learned intermediary doctrine and evidentiary limits in product liability cases. It reinforces several principles that will be important to manufacturers defending failure-to-warn claims in Illinois.

The plaintiff alleged that Mead Johnson's preterm infant formula caused the infant to develop NEC and asserted claims for design defect, failure to warn, and negligence. After a jury returned a verdict in favor of the plaintiff, Mead Johnson appealed on numerous grounds. The appellate court ultimately reversed and remanded for a new trial.

The Learned Intermediary Doctrine Applies

The most significant aspect of the decision is the court's application of the learned intermediary doctrine.

Although the formula at issue was not a prescription drug, the court concluded that the doctrine nevertheless applied because the product was used exclusively in the highly specialized environment of a neonatal intensive care unit. Physicians—not parents—evaluated the infant's condition, exercised clinical judgment regarding available feeding options, ordered the formula, and supervised its administration.

The court held that under these circumstances any duty to warn ran to the treating physicians rather than directly to the patient's mother. Because the trial court instructed the jury that the manufacturer owed a duty to warn both the physicians and the mother, the appellate court found the jury had been instructed under an incorrect legal standard, requiring reversal and remand for a new trial.

The opinion makes clear that courts may look beyond whether a product technically requires a prescription and instead focuses on how the product is actually selected, prescribed, and administered in practice.

A Reminder on Evidence of Corporate Wealth

The appellate court also provided important guidance regarding the admissibility of financial evidence.

At trial, the plaintiff introduced extensive evidence concerning Mead Johnson's revenues, executive compensation, profitability, and corporate financial structure despite not seeking punitive damages. The appellate court concluded that this evidence carried a substantial risk of unfair prejudice while offering little probative value on liability issues with respect to the liability issues before the jury.

The court cautioned that evidence of a defendant's financial condition should not be used to portray a company as wealthy or profit-driven when compensatory damages are the only issue before the jury. Absent a claim for punitive damages, such evidence may improperly invite jurors to decide a case based on perceptions of corporate wealth rather than the merits of the underlying claims. This portion of the opinion will likely become an important reference for defense counsel seeking to limit inflammatory financial evidence in future trials.

Practical Takeaways for Product Manufacturers

The decision offers several practical lessons for companies defending product liability claims:

• Courts may extend the learned intermediary doctrine beyond traditional prescription drugs and medical devices when products are selected and administered through physician-directed medical judgment in a clinical setting.
• Courts may look beyond a product’s regulatory classification and instead focus on how the product is selected, prescribed, and administered in practice.
• Defense counsel should carefully preserve jury instruction issues for appeal, particularly where the existence and scope of a legal duty are disputed or where an instruction may affect the applicable standard of care.
• Courts remain willing to exclude, and in some cases reverse judgments based upon, the admission of prejudicial financial evidence that is unrelated to the issues the jury must decide.

Looking Ahead

The Fifth District's opinion represents a significant development in Illinois product liability law expanding on Kirk v Michael Reese Hospital & Medical Center, 117 Ill.2d 507 (1987) and Hansen v. Baxter Healthcare Corp., 198 ILL.2d 420 (2002) which applied the learned intermediary doctrine to prescription drugs and medical devices. Although the court did not resolve every issue raised on appeal, its analysis provides meaningful guidance on the scope of the learned intermediary doctrine and the limits of admissible evidence in complex product liability cases. Manufacturers and defense counsel will likely look to the decision in future disputes involving physician-directed products, failure-to-warn claims, and challenges to potentially prejudicial financial evidence.